Latest data from January 14, 2022
Number of Health Center respondents = 6 (75% of all Health Centers)
Data represents information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, Antigen)1 | 13,464 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, Antigen) | 70.41% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen)1 | 4,671 |
| Racial and/or Ethnic Minority Patients Tested Positive for COVID-19, Virus Detection (PCR, Antigen) | 78.02% |
Patients by Race and Ethnicity
| Race/Ethnicity | Patients Tested, Virus Detection (PCR, Antigen)2 | Patients Tested Positive, Virus Detection (PCR, Antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 24.03% | 17.66% |
| White, Hispanic/Latino Patients | 22.30% | 24.60% |
| Black/African American, Non-Hispanic/Latino Patients | 6.75% | 5.91% |
| Black/African American, Hispanic/Latino Patients | 2.92% | 3.32% |
| Asian Patients3 | 1.57% | 1.54% |
| American Indian/Alaska Native Patients3 | 0.23% | 0.30% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.66% | 0.47% |
| Patients with More Than One Race3 | 8.15% | 9.23% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 14.62% | 17.34% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.29% | 2.53% |
| Unreported/Refused to Report Race and Ethnicity | 16.48% | 17.11% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 502 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 66.30% |
| COVID-19 Immunization Series Completed | 472 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 60.73% |
| COVID-19 Immunization Series Additional | 960 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 43.56% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 30.88% | 34.11% | 52.92% |
| White, Hispanic/Latino Patients | 20.92% | 16.74% | 10.42% |
| Black/African American, Non-Hispanic/Latino Patients | 6.18% | 6.78% | 8.02% |
| Black/African American, Hispanic/Latino Patients | 3.59% | 1.48% | 1.15% |
| Asian Patients3 | 2.79% | 2.33% | 4.27% |
| American Indian/Alaska Native Patients3 | 0.20% | 0.42% | 0.52% |
| Native Hawaiian/Other Pacific Islander Patients3 | 1.99% | 1.48% | 0.62% |
| Patients with More Than One Race3 | 7.17% | 5.08% | 4.90% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 17.93% | 18.43% | 10.94% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.39% | 3.81% | 3.23% |
| Unreported/Refused to Report Race and Ethnicity | 5.98% | 9.32% | 3.02% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, Antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 16.67% |
| 1 to 24 Hours | 0.00% |
| More Than 24 Hours | 83.33% |
| N/A | 0.00% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 0.00% |
| Staffing to administer the vaccine | 50.00% |
| Vaccine confidence | 16.67% |
| Vaccine storage capacity | 0.00% |
| Vaccine supply | 0.00% |
| Other | 0.00% |
| None | 33.33% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 0.00% |
| Average Percent of Health Center Visits Conducted Virtually | 42.50% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 33.33% |
| Number of Mobile Van Sites | 0 |
| Number of Pop-up Clinics | 4 |
| Number of School-Based Vaccination Sites | 30 |
| Number of Family Vaccination Clinics | 30 |
Monoclonal Antibody Therapy
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 16.67% |
| Refer patients to another organization that provides monoclonal antibody therapies | 33.33% |
| None | 50.00% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 0.00% |
| Patient awareness/education | 0.00% |
| Staffing capacity | 50.00% |
| Therapy administration/onsite logistics | 16.67% |
| Other | 0.00% |
| None | 50.00% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 1 |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 2,250 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provide to Existing Health Center Patients | 100.00% |
| Provide to General Public Who Came to the Health Center | 100.00% |
| Provide at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 0.00% |
| Provide at Other Community Events | 0.00% |
| Provide through direct outreach to specific populations (i.e., individuals experiencing homelessness, MSAWs, residents of public housing, individuals with limited English proficiency) | 0.00% |
| Other | 0.00% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 1 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication5 | 0.00% |
Oral Antiviral Medication Distribution by Race and Ethnicity5
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | 100.00% |
| White, Hispanic/Latino Patients | 0.00% |
| Black/African American, Non-Hispanic/Latino Patients | 0.00% |
| Black/African American, Hispanic/Latino Patients | 0.00% |
| Asian Patients3 | 0.00% |
| American Indian/Alaska Native Patients3 | 0.00% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.00% |
| Patients with More Than One Race3 | 0.00% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.00% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.00% |
| Unreported/Refused to Report Race and Ethnicity | 0.00% |
Oral Antiviral Medication Distribution by Special/Vulnerable Population5
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | 0.00% |
| Patients Experiencing Homelessness | 0.00% |
| Patients Who Are Residents of Public Housing | 0.00% |
| Patients with Limited English Proficiency | 0.00% |
| Children Under 18 Years of Age | 0.00% |
1 The reported number of patients tested do not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed courses of COVID-19 oral antiviral medication received through the HRSA Health Center COVID-19 Therapeutics Program as the denominator.
